A p-value of 0.38? NEJM results raise new questions for Eli Lilly's vaunted Covid antibody
Generally, a p-value of 0.38 means your drug failed and by a fair margin. Depending on the company, the compound and the trial, it might mean the end of the program. It could trigger layoffs.
For Eli Lilly, though, it was part of the key endpoint on a trial that landed them a $1.2 billion deal with the US government to supply up to nearly 1 million Covid-19 antibodies.
So what does one make of that? Was the endpoint not so important, as Lilly maintains? Or did the US government promise a princely sum for a pedestrian drug?
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,400+ biopharma pros reading Endpoints daily — and it's free.